Growth Signals: Sema4 Navigates Precision Medicine with $500M SPAC
Growth Signals: Sema4 Navigates Precision Medicine with $500M SPAC Founder and CEO Eric Schadt, PhD, discusses the genomic and clinical data company’s approach to ‘health intelligence’ with GEN Edge. July 26, 2021 Eric Schadt, PhD, Sema4’s Founder and CEO, says his company’s going public through a just-completed $500 million SPAC deal will enhance its competitiveness as it strives to offer more holistic precision medicine solutions for health systems and biopharmas. The company employs just over 1,000 people. [Sema4] Share Sema4 has signaled its intent to grow into a juggernaut of p...